BioMedNewsBreaks

MondayFeb 24, 2025 9:23 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Launches “CLD-101” Trial for High-Grade Glioma at Northwestern

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted antitumor virotherapies, said Northwestern University/Northwestern Memorial Hospital is recruiting for its Phase 1B/2 clinical trial of "CLD-101" in newly diagnosed high-grade glioma patients. The company completed shipment of the first batch of CLD-101—comprising allogeneic neural stem cells loaded with the oncolytic adenovirus CRAd-S-pk7—to support the trial, which builds on promising Phase 1 results in 12 patients published in The Lancet Oncology. The physician-led and NCI-sponsored study, headed by Dr Maciej Lesniak and Dr Roger Stupp and funded by the NIH/NCI SPORE, aims to evaluate a multiple-dose regimen that could…

Continue Reading

FridayFeb 21, 2025 8:30 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at European Life Sciences CEO Forum

CNS Pharmaceuticals (NASDAQ: CNSP) announced that CEO John Climaco will present at the 18th Annual European Life Sciences CEO Forum in Zurich on Feb. 26, 2025, at 3:20 p.m. CET / 9:20 a.m. EST; management will also be available for one-on-one meetings with registered investors, and a video webcast of the presentation will be accessible on-demand through the conference presenters portal. To view the full press release, visit https://ibn.fm/yGKfB About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central…

Continue Reading

ThursdayFeb 20, 2025 1:29 pm

BioMedNewsBreaks — Adageis: Championing the Future of Healthcare with Powerful AI Tools

Adageis is positioned for opportunity as artificial intelligence reshapes healthcare. The technology company offers “flexible AI-centric software solutions for healthcare systems and providers in an easy-to-use application driving higher revenue… Its powerful and patented AI-centric ProActive Care Platform integrates seamlessly into existing workflows, making it an ideal partner for organizations navigating the shift toward value-based care,” reads a recent article. “Adageis’ proactive efficiency tools enable real-time monitoring, ensuring that patients receive timely interventions between visits. This approach reduces emergency department utilization and improves patient satisfaction… By prioritizing targeted solutions, Adageis not only transforms care delivery but also sets a benchmark for…

Continue Reading

ThursdayFeb 20, 2025 8:30 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor Conference

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the Virtual Investor Top 5 for ‘25 On-Demand Conference, where CEO John Climaco outlined five key reasons for investors and industry peers to follow the company in 2025. The presentation focused on CNS Pharmaceuticals’ advancements in developing treatments for primary and metastatic brain and central nervous system cancers, emphasizing its strategic initiatives and clinical progress for the year ahead. To view the full press release, visit https://ibn.fm/3gUjC About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic…

Continue Reading

WednesdayFeb 19, 2025 10:49 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Host Patient Forum on Alzheimer’s and Parkinson’s Trials

Annovis Bio (NYSE: ANVS) will host a live webcast on Feb. 27, 2025, at 4:30 p.m. EST, where CEO Maria Maccecchini, Ph.D., will answer questions from patients, caregivers, and families regarding the company’s clinical trials and future plans. The forum will provide updates on the ongoing Phase 3 Alzheimer’s disease trial, plans for the Phase 3 Parkinson’s disease study, and patient communication strategies. A brief presentation will precede a Q&A session, with attendees encouraged to submit questions in advance. The event underscores Annovis’ commitment to patient engagement and transparency. To view the full press release, visit https://ibn.fm/aFJV6 About Annovis Bio…

Continue Reading

WednesdayFeb 19, 2025 10:33 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 1-for-50 Reverse Stock Split

CNS Pharmaceuticals (NASDAQ: CNSP) announced a 1-for-50 reverse stock split of its common stock, set to take effect on Feb. 21, 2025. The company’s shares will continue trading on Nasdaq under the symbol “CNSP” but with a new CUSIP number: 18978H409. The reverse split aims to increase the per-share trading price and ensure compliance with Nasdaq’s minimum share price requirement. As a result, every 50 shares of common stock will be consolidated into one, with proportional adjustments made to outstanding equity awards and warrants. No fractional shares will be issued, with cash payments provided instead. The number of authorized shares…

Continue Reading

TuesdayFeb 18, 2025 12:46 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at 6th Glioblastoma Drug Development Summit

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the 6th Glioblastoma Drug Development Summit, taking place Feb. 18-20, 2025, in Boston. Chief Medical Officer Dr. Sandra Silberman will present on Feb. 20 at 10:45 a.m. ET, discussing novel formulations of anthracyclines and taxanes designed to cross the blood-brain barrier. The company’s lead candidate, Berubicin, has completed patient enrollment in a pivotal study against glioblastoma, with primary analysis data expected in the first half of 2025. CNS Pharmaceuticals is also advancing TPI 287 and plans to engage with the FDA on trial design. Berubicin has received Fast Track and Orphan Drug…

Continue Reading

FridayFeb 14, 2025 3:48 pm

BioMedNewsBreaks — Adageis Bringing AI Solutions to Identify High-Risk Patients, Address Care Gaps

Adageis is reshaping the healthcare landscape, offering solutions designed to streamline workflows and align incentives with quality care outcomes. “Central to this approach is the company’s ProActive Care Platform, a patented AI-powered system that provides actionable insights to healthcare providers. The platform equips Accountable Care Organizations (‘ACOs’), Clinically Integrated Networks (‘CINs’), and Independent Physician Associations (‘IPAs’) with the tools to deliver high-quality care while meeting the financial goals of value-based models,” reads a recent article. “At the heart of the platform lies the Patented Risk Engine (‘PRE’), an AI-driven tool that analyzes patient data to identify high-risk individuals and care gaps.…

Continue Reading

ThursdayFeb 13, 2025 1:25 pm

BioMedNewsBreaks – Astiva Health Expands Community Engagement with New Activity Center in San Jose

Astiva Health announced the grand opening of its new Activity Center in San Jose, reinforcing its commitment to community wellness. The facility will serve as a hub for local seniors, offering various health and wellness programs designed to enhance quality of life. The initiative aligns with Astiva Health’s mission to provide accessible healthcare solutions and foster social engagement among its members. To view the full press release, visit https://ibn.fm/4Wlwb About Astiva Health Astiva is a leader in culturally responsive health care solutions, committed to bridging health care gaps for diverse and underserved populations. With a focus on delivering personalized care,…

Continue Reading

ThursdayFeb 13, 2025 12:02 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Prices $10 Million Public Offering at $1.70 Per Share

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care, announced the pricing of its public offering of 5,882,353 shares at $1.70 per share, expecting to raise $10 million before deductions. The offering, underwritten by MDB Capital with Paulson Investment Company LLC participating as a selected dealer, is set to close on or about Feb. 14, 2025, subject to conditions. Proceeds will support commercial-readiness efforts, R&D, clinical and regulatory projects, and general corporate purposes. The underwriter has a 45-day option to purchase up to 882,353 additional shares to cover over-allotments. To view the full press release, visit https://ibn.fm/wzvyh About…

Continue Reading